MoonLake Immunotherapeutics Q1 EPS missed estimates and stock fell, but keep "buy" ratings.

MoonLake Immunotherapeutics (MLTX) reported Q1 EPS miss of ($0.39) vs. ($0.28) est., and stock fell $1.80 to $44.25. Despite this, Needham, HC Wainwright, and Oppenheimer kept "buy" ratings, with price targets ranging from $62-$104. MLTX, a clinical-stage biopharma, focuses on inflammation disease therapies like Sonelokimab.